SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jeffbas who wrote (130)10/18/1999 10:33:00 PM
From: scaram(o)uche  Read Replies (1) of 438
 
Already gone back to the drawing board, for two-antigen combos. I believe that the company will see the current trials through to completion. There is no doubt that they are poking around with transfected dendritic cells, and Rosenberg's lab is working with receptor-transfected T cells, so..... given the CEGE patents, we may see a *new* trial in the near future? However, it won't be drawing board time, IMO.

I'm here for the ATIII. Lots of projects are of interest, but I'm here for the ATIII.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News